Hilltop Bio lands RevUp Capital debt backing for its animal regenerative therapies
What's the deal? Hilltop BioDealroom has a profile for this one. Try Dealroom → has secured follow-on debt financing from RevUp CapitalDealroom has a profile for this one. Try Dealroom →, which first backed the Norwood, Massachusetts company earlier. RevUp described itself as "thrilled to deepen our support" for the veterinary biotech, founded in 2018.
What's the endgame? Hilltop sells off-the-shelf regenerative therapies that help horses and dogs heal from injury and disease. Its products target joint health, soft tissue repair, and ophthalmology, built on a proprietary process called BioStabyl designed to keep healing components in biological material intact.
Why now? The raise builds on momentum. In January 2025, Hilltop announced $5 million in strategic funding, citing 100% year-over-year sales growth, more than 200 new veterinary practices, and 6,000 animals served in 2024.
Veterinarians across the US now use Hilltop's shelf-stable products, from general practitioners to specialists in surgery, sports medicine, and rehabilitation. The company sells through national distributors and serves equine and canine patients, from elite athletes to family pets.
Who's behind it? Founder and chief executive officer Amanda Drobnis, a lifelong equestrian, started the company after a serious hip injury at 29 led her to choose an experimental regenerative treatment over a full hip replacement. "Within weeks, she was back on her feet and back in the saddle," RevUp said. Early backers include Cherrystone Angel Group and Launchpad Venture GroupDealroom has a profile for this one. Try Dealroom →; the company has raised $8.92 million to date.
The signal: Hilltop's raise fits a broader push to commercialize advanced veterinary treatments. Rejuvenate Bio raised $6 million in June 2026 alongside an R&D tie-up with Merck Animal HealthDealroom has a profile for this one. Try Dealroom →, while GallantDealroom has a profile for this one. Try Dealroom → raised $18 million in 2025 for stem-cell therapies — a sign that investor interest in animal-health regenerative medicine keeps building.
Read more: revupfund.com
Image credit: USAG-Humphreys
